TRCT
PRQR icon

Tower Research Capital (TRC)’s ProQR Therapeutics PRQR Stock Holding History

Tower Research Capital (TRC)’s Portfolio PRQR Stock Details PRQR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-1,211
Closed -$2.45K – 5463
2025
Q4 		$2.45K Buy
1,211
+318
+36% +$743 ﹤0.01% 4524
2025
Q3 		$1.9K Buy
+893
New +$1.95K ﹤0.01% 4714
2025
Q1 		– Sell
-3,632
Closed -$9.63K – 5658
2024
Q4 		$9.63K Buy
+3,632
New +$11.5K ﹤0.01% 3891
2024
Q3 		– Sell
-821
Closed -$1.36K – 5921
2024
Q2 		$1.36K Buy
+821
New +$1.59K ﹤0.01% 5167
2024
Q1 		– Sell
-3,536
Closed -$7K – 6076
2023
Q4 		$7K Buy
+3,536
New +$5.43K ﹤0.01% 4674
2023
Q2 		– Sell
-14,132
Closed -$30K – 6295
2023
Q1 		$30K Buy
14,132
+8,796
+165% +$26.9K ﹤0.01% 3002
2022
Q4 		$20K Sell
5,336
-7,938
-60% -$10.4K ﹤0.01% 3141
2022
Q3 		$10K Sell
13,274
-4,883
-27% -$3.92K ﹤0.01% 4566
2022
Q2 		$14K Buy
18,157
+15,895
+703% +$11.8K ﹤0.01% 4157
2022
Q1 		$2K Buy
2,262
+328
+17% +$1.1K ﹤0.01% 5584
2021
Q4 		$16K Buy
+1,934
New +$14.7K ﹤0.01% 3929
2021
Q2 		– Sell
-15,646
Closed -$103K – 5756
2021
Q1 		$103K Buy
15,646
+15,446
+7,723% +$78.9K ﹤0.01% 2563
2020
Q4 		$1K Sell
200
-8,759
-98% -$37K ﹤0.01% 5024
2020
Q3 		$43K Buy
8,959
+7,639
+579% +$40K ﹤0.01% 3596
2020
Q2 		$8K Buy
1,320
+1,012
+329% +$5.47K ﹤0.01% 4114
2020
Q1 		$2K Sell
308
-3,765
-92% -$28.9K ﹤0.01% 2626
2019
Q4 		$40K Buy
+4,073
New +$31.7K ﹤0.01% 1476
2019
Q3 		– Sell
-8,647
Closed -$79K – 4432
2019
Q2 		$79K Buy
+8,647
New +$102K 0.01% 1297
2019
Q1 		– Sell
-559
Closed -$9K – 4177
2018
Q4 		$9K Buy
559
+413
+283% +$7.58K ﹤0.01% 2564
2018
Q3 		$3K Buy
+146
New +$1.55K ﹤0.01% 3324
2018
Q2 		– Sell
-1,590
Closed -$5K – 3965
2018
Q1 		$5K Sell
1,590
-685
-30% -$2.2K ﹤0.01% 2719
2017
Q4 		$7K Sell
2,275
-664
-23% -$2.38K ﹤0.01% 2751
2017
Q3 		$14K Buy
+2,939
New +$15.3K ﹤0.01% 2919
2016
Q4 		– Sell
-785
Closed -$5K – 4279
2016
Q3 		$5K Hold
785
– – ﹤0.01% 2569
2016
Q2 		$4K Buy
785
+159
+25% +$818 ﹤0.01% 3546
2016
Q1 		$3K Buy
626
+515
+464% +$2.62K ﹤0.01% 3145
2015
Q4 		$1K Sell
111
-791
-88% -$9.1K ﹤0.01% 4139
2015
Q3 		$13K Buy
902
+424
+89% +$7.1K ﹤0.01% 2101
2015
Q2 		$8K Buy
478
+264
+123% +$4.97K ﹤0.01% 2901
2015
Q1 		$5K Buy
+214
New +$4.42K ﹤0.01% 3261

Other funds holding PRQR

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
PFM
Privium Fund Management Amsterdam, Netherlands $480M AUM 77.45% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
PIM
Platinum Investment Management Sydney Australia 2000, Australia $397M AUM 63.96% 1-Year Est. Return

Tower Research Capital (TRC)'s PRQR Position: Q1 2026 in Review

Tower Research Capital (TRC) sold out of ProQR Therapeutics (PRQR) in Q1 2026, closing a stake of 1,211 shares — an estimated $2.45K sold.

Tower Research Capital (TRC) first reported a position in PRQR in Q1 2015 and held it in 30 quarters. The position peaked at $103K in Q1 2021. 69 funds tracked by Wall St. Rank hold PRQR as of Q1 2026.

  • Tower Research Capital (TRC) reported no remaining ProQR Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Tower Research Capital (TRC) sold 1,211 ProQR Therapeutics shares in Q1 2026, an estimated $2.45K.
  • Tower Research Capital (TRC) first reported a position in ProQR Therapeutics in Q1 2015 and held it in 30 quarters.
  • Tower Research Capital (TRC)'s ProQR Therapeutics position peaked at $103K in Q1 2021.
  • 69 funds tracked by Wall St. Rank held ProQR Therapeutics as of Q1 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q1 2026, filed 15 May 2026.